VCU Massey scientists pinpoint druggable target in TNBC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Through a genomic screening method known as CRISPR/CAS9 screening, Massey scientists—led by Anthony Faber and Jennifer Koblinski—identified a specific enzyme called UBA1 that revealed itself as an ideal therapeutic target in triple negative breast cancer. Using a novel UBA-inhibiting drug called TAK-243, they blocked the cellular function of UBA1 and effectively killed cancer cells in patient-derived breast tumors in mice.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

From left to right: Geoffrey Shapiro, Leif Ellisen and Nancy Lin. Sitting below them is Kornelia Polyak.The Dana-Farber/Harvard Cancer Center,  a cancer research consortium comprised of five of Boston’s academic medical centers, including Dana-Farber Cancer Institute and Massachusetts General Hospital, has been awarded an NCI grant to continue its Specialized Program of Research Excellence in Breast Cancer.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login